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SIGN-R1 is a principal receptor for microbial poly-
saccharides uptake and is responsible for C3 fixation
via an unusual complement activation pathway on
splenicmarginal zonemacrophages. In thesemacro-
phages, SIGN-R1 is also involved in anti-inflamma-
tory activity of intravenous immunoglobulin by direct
interaction with sialylated Fcs. The high-resolution
crystal structures of SIGN-R1 carbohydrate recogni-
tion domain and its complexes with dextran sulfate
or sialic acid, and of the sialylated Fc antibody pro-
vide insights into SIGN-R1’s selective recognition
of a-2,6-sialylated glycoproteins. Unexpectedly, an
additional binding site has been found in the SIGN-
R1 carbohydrate recognition domain, structurally
separate from the calcium-dependent carbohy-
drate-binding site. This secondary binding site could
bind repetitivemolecular patterns, as observed inmi-
crobial polysaccharides, in a calcium-independent
manner. These two binding sites may allow SIGN-
R1 to simultaneously bind both immune glycopro-
teins and microbial polysaccharide components,
accommodating SIGN-R1’s ability to relate the
recognition of microbes to the activation of the clas-
sical complement pathway.
INTRODUCTION
The classical pathway is one of the major complement activation
mechanisms and is required for innate protection against patho-
genic microorganisms including Streptococcus pneumoniae
(Brown et al., 2002). A pivotal step in the complement activation
pathway is the assembly of C3 convertase, which digests the
complement components to form C3 fragments that bind to mi-
crobes and make them recognized by leukocytes. Deposition
and activation of C3 convertase over the bacterial surface initi-Structure 22, 1595–16ates the complement cascade leading to the elimination of the
microbes. However, encapsulated microorganisms like S. pneu-
moniae are able to resist to the complement pathway by limiting
access to the cell surface and reducing the amount of C3
deposition (Abeyta et al., 2003). To overcome this problem,
hosts have developed an alternative strategy for specific path-
ogen detection by pattern recognition receptors (PRRs). PRRs
discriminate the molecular patterns expressed by pathogens
and thus facilitate differential recognition of pathogens and their
products by the immune system (Gordon, 2002).
C-type lectin receptors (CLRs) are one kind of PRRs ex-
pressed by a broad spectrum of cells, including dendritic
cells (DCs), macrophages, and other antigen-presenting cells
(Meyer-Wentrup et al., 2005). Increasing evidence has shown
that the roles played by several members of the CLR family
are critical for innate immunity. SIGN-R1 or CD209b is one of
the eight mouse homologs of human CLR named DC-SIGN or
CD209 (Park et al., 2001; Powlesland et al., 2006). Unlike human
DC-SIGN/CD209, three of mouse SIGN family molecules are
found to be expressed in the immune system: DC-SIGN/
CD209a, SIGN-R1/CD209b, and SIGN-R3/CD209d. Whereas
human DC-SIGN is expressed in both dendritic cells and macro-
phages (Geijtenbeek et al., 2000; Granelli-Piperno et al., 2005),
the expression of three mouse SIGN homologs is detected in
different levels from distinct populations of dendritic cells and
macrophages (Cheong et al., 2010; Kang et al., 2003; Nagaoka
et al., 2010). Of three homologs, mouse DC-SIGN lacks polysac-
charide binding, whereas SIGN-R1, similar to human DC-SIGN,
binds a broad variety of microbial organisms and their polysac-
charides and SIGN-R3 binds a fewer number of ligands (Camin-
schi et al., 2006; Galustian et al., 2004; Takahara et al., 2004).
SIGN-R1 is expressed at high levels in macrophages within
the splenic marginal zone and lymph node medulla and is also
a principal receptor for taking up microbial polysaccharides
such as dextran or capsular polysaccharides of S. pneumoniae
(CPSs; Geijtenbeek et al., 2002; Kang et al., 2003, 2004). In vivo
inactivation of SIGN-R1 inhibits clearance of S. pneumoniae
by preventing macrophages from phagocytosis, blocks com-
plement-dependent deposition of CPS on splenic follicles,
and therefore makes mice more susceptible to pneumococcal06, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1595
Figure 1. Oligosaccharide Structure
(A) Structure of the full carbohydrate moiety linked
to Asn of antibody Fc fragment and subunit A of
globular domain of C1q. The sialic acid used in this
study is boxed in red.
(B) Structure of the dextran sulfate polysaccharide
showing heterogeneous sulfate substitutions.
The tetrasaccharide fragment observed in one
SIGN-R1 complex is boxed in blue, and two di-
saccharides also found in complex with SIGN-R1
are boxed in yellow and green.
(C) Repeating unit of capsular polysaccharide
belonging to 14 serotype of S. pneumoniae. Glc,
glucose; Fuc, fucose; Gal, galactose; GlcNAc,
N-acetylglucosamine;Man,manose; NeuAc, sialic
acid.
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Basis for Selective Recognition by SIGN-R1infection (Geijtenbeek et al., 2002; Kang et al., 2003, 2004, 2006;
Lanoue et al., 2004). This defect in innate immunity against S.
pneumoniae after inactivation of SIGN-R1 suggests a link be-
tween SIGN-R1 and the fixation of C3 opsonins on CPS. This
connection was revealed by an unusual complement activation
pathway against CPSmediated by SIGN-R1 on splenic marginal
zone macrophages (Kang et al., 2006). Binding of CPS to SIGN-
R1 initiates an immunoglobulin (Ig)-independent activation of
complements for the fixation of C3 on CPS, where the direct
interaction between SIGN-R1 and C1q triggers the classical
complement pathway. This complement activation strategy in
splenic marginal zone macrophages prevents S. pneumoniae
from escaping C3 opsonization (Kang et al., 2006). In this mech-
anism, it is critical that SIGN-R1 molecule can function in both
processes, i.e., the recognition and binding of a pathogen and
the activation of classical complement pathway, which is likely
to require SIGN-R1 to bind both CPS and C1q simultaneously.
In addition, it has been reported that SIGN-R1 clears out the cells
via interaction with C1q fixed on apoptotic cells, thus increasing
the C3 fixation (i.e., complement activation) on the apoptotic
cells, and reducing autoimmunity (Prabagar et al., 2013).
The cause of anti-inflammatory activity of intravenous Ig (IVIG)
was contributed to a minor population of the pooled IgG mole-
cules that contains terminal a-2,6-sialic acid linkages on their
Fc-linked glycans (Kaneko et al., 2006). It was reported that
SIGN-R1 in splenic marginal zone macrophages preferentially
binds to the sialylated Fcs and that the in vivo inactivation of
SIGN-R1 eliminates the anti-inflammatory activity of IVIG and
intravenous sialylated Fcs (Anthony et al., 2008). This interaction
between SIGN-R1 and sialylated Fcs was shown to accomplish
the anti-inflammatory activity via a different Th2 cytokine
pathway (Anthony et al., 2011). Therefore, SIGN-R1 is a single
member of the mouse SIGNCLR family that functions by binding
polysaccharides from both endogenous and microbial origins.
We report herein the high-resolution crystal structures of the
carbohydrate recognition domain of SIGN-R1 (CRD_SIGN-R1)
as well as their complexes with dextran sulfate (DexS) and sialic
acid (N-acetylneuraminic acid [NeuAc]; Figure 1). In addition, the1596 Structure 22, 1595–1606, November 4, 2014 ª2014 Elsevier Ltd All rights reservedhigh-resolution crystal structure of the
sialylated Fc antibody portion obtained
in this work together with molecular
dynamics calculations, provides insightsinto SIGN-R1’s selective recognition of a-2,6-sialylated glyco-
proteins relevant to the role of SIGN-R1 in anti-inflammatory
activity of IVIG. Structural, computational and biochemical
experiments reveal that sialylated glycoproteins, such as C1q
and Ig, bind SIGN-R1 through the classical calcium-dependent
carbohydrate recognition site, whereas the binding of microbial
pathogens can also use the additional calcium-independent
substrate-binding site, thereby allowing SIGN-R1 to simulta-
neously bind both immune glycoproteins and microbial
components.
RESULTS AND DISCUSSION
Overall CRD_SIGN-R1 Structure
With the extracellular domain of SIGN-R1 (ECD_SIGN-R1) pro-
duced as monomers from Escherichia coli, crystals could not
be generated (P. Li, personal communication). In addition, with
the ECD_SIGN-R1 produced as His-tagged monomers in
E. coli, carbohydrate binding could not be detected even after
oligomerizationwith anti-His antibody (T. Feizi, personal commu-
nication). Powlesland and colleagues also reported that the
ECD_SIGN-R1 produced fromE. coliwas unable to bind any car-
bohydrates as monomers (Powlesland et al., 2006). Therefore, it
is likely that the ECD_SIGN-R1 or CRD_SIGN-R1 proteins pre-
pared from E. coli are not properly folded. Previously, however,
we had successfully performed the carbohydrate binding ana-
lyses of SIGN-R1, where the soluble Fc-fused ECD_SIGN-R1
was expressed and purified directly from the culture supernatant
of transfectant Chinese hamster ovary (CHO) cells (Galustian
et al., 2004). Therefore, we prepared the soluble CRD_SIGN-R1
(amino acid residues from Cys192 to Gly325) from the culture
supernatant of transfectant CHO cells and made its crystals
successfully (Silva-Martin et al., 2009).
High-resolution crystal structures for CRD_SIGN-R1 and its
complexes with dextran sulfate (SIGN-R1:DexS) and sialic
acid (SIGN-R1:NeuAc) have been solved in this study (Table
1). The asymmetric unit is composed of four nearly identical
monomers with an average root-mean-square deviation (rmsd)
Table 1. Data Collection and Refinement Statistics
CRD-SIGN-R1 CRD-SIGN-R1:DexS CRD-SIGN-R1:NeuAc FC_Sial
Data Collection
Space group C2 C2 C2 P212121
Cell dimensions
a, b, c (A˚) 146.72, 92.77, 77.06 144.03, 97.96, 73.84 146.20, 94.47, 76.14 49.59, 80.15, 140.21
a, b, g () 90, 121.66, 90 90, 120.86, 90 90, 121.42, 90 90, 90, 90
Temperature (K) 100 100 100 100
Wavelength (A˚) 1.07225 0.9334 0.87260 0.999
Resolution (A˚) 74.53–(1.98–1.87) 61.815–(2.98–2.58) 42.98–(2.95–2.80) 42.17–(2.42–2.30)
No. unique reflections 52,474 (2,478) 30,140 (2,478) 21,870 (3,185) 25,633 (3,662)
Rsym
a 0.06 (0.54) 0.11 (0.28) 0.11 (0.45) 0.09 (0.51)
Average I/s(I) 11.80 (1.70) 6.2 (1.8) 9.4 (3.7) 11.7 (3.5)
Completeness (%) 93 (72) 99 (99) 100 (100) 99.9 (100)
Redundancy 5.7 (5.4) 4.4 (2.4) 2.3 (2.3) 6.4 (6.6)
Refinement
Resolution (A˚) 27.63–1.87 40.00–2.6 40.31–2.80 20.10–2.03
R/Rfree (%) 20.45/24.43 20.05/24.74 18.06/26.21 23.64/28.21
No. atoms
Protein 4,292 4,315 4,295 3,316
Water 407 168 479 82
Ligand – 147 63 221
Metal ions (Ca) 4 4 4 –
SO4 24 12 30 –
B-factor (A˚2)
Protein 34.29 30.74 26.55 42.82
Ligands – 63.45 59.69 61.15
Water 24.88 23.70 24.67 37.63
Rmsds
Bond length (A˚) 0.012 0.011 0.018 0.011
Bond angles () 1.063 1.257 1.141 1.257
PDB code 3ZHG 4C9F 4CAJ 4CDH
Value for the highest resolution shell is shown in parentheses.
aRsym = Sj I  Iav j/ S I, where the summation is over symmetry equivalent reflections.
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Basis for Selective Recognition by SIGN-R1value of 0.182 A˚ over 126 aligned Ca atoms. The CRD_SIGN-R1
structure (Figure 2A) exhibits one large b strand (b2), which di-
vides the framework in two lobes. The upper lobe comprises b
strands 2 to 4 and the a3 helix. The lectin characteristic long
loop region (LLR) involved in calcium-mediated carbohydrate
binding is found between a3 and b3 (Tyr280 to Asp293; Figure 1).
The lower lobe includes the N-terminal and the C-terminal ex-
tremes, coming close together to form an antiparallel b sheet
that is flanked by a1 and a2, one on each side. Eight cysteines
are involved in the formation of four disulfide bridges, three of
them stabilizing the lower lobe, while the fourth is located be-
tween both lobes. The ‘‘WMGL’’ motif present in all C-type lectin
proteins reported (Zelensky and Gready, 2003) is also present in
SIGN-R1 (residues 253–256). This pattern unites a cluster of hy-
drophobic residues stabilizing all parts of the structure. The hu-
man C-type lectin DC-SIGN (Protein Data Bank [PDB] code
2IT6) is the most closely related structure to SIGN-R1, with
69% of sequence identity and an rmsd of 1.32 A˚ over 131
aligned C-alpha atoms.Structure 22, 1595–16SIGN-R1 presents six sulfate molecules bound to each mono-
mer (Figure 2A); S1 is near the calcium+-mediated carbohydrate
binding site, S6 is placed in the lower lobe near the N-terminal
and the C-terminal extremes, and four sulfate molecules (S2–
S5) are placed at the opposite face of the calcium-mediated
carbohydrate binding site (Figure 2A). Interestingly these four
sulfates are located inside a positively charged groove in collar
pattern disposition, retaining a similar distance among them
(8.70 A˚, 9.94 A˚, and 8.46 A˚; Figure 2B).
Calcium-Binding Site in SIGN-R1
In general, altogether, four Ca2+-binding sites occur in different
subgroups of the C-type lectin-like domain (CTLD) family (Zelen-
sky and Gready, 2003). In the crystal structure of SIGN-R1 only
one, that of the characteristic C-type lectin sugar-binding site,
is observed (Figure 2A). This Ca2+ is stabilized by carboxylate
or carboxyamide groups of Glu285, Asn287, Glu292, and
Asp304 and by two water molecules, providing an octahedral
coordination for the cation (Figure S1A available online). All these06, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1597
Figure 2. 3D Structure of CRD_SIGN-R1
(A) Overall view of the ribbon representation of CRD_SIGN-R1. The Ca2+ ion (Ca1) is represented as a green sphere, and the six bound sulfate molecules (S1–S6)
are drawn as capped sticks. Disulfide bridges are shown as purple sticks.
(B) Stabilization of four sulfate molecules (S2–S5) placed at the opposite face of the primary carbohydrate binding site. Residues involved in sulfate stabilization
are labeled and represented as capped sticks. Polar interactions are represented as dotted lines and distances among sulfates are also indicated.
(C) Structural superimposition of SIGN-R1 (brown), DC-SIGN (blue), DC-SIGNR (light green), and the apo form of DC-SIGNR (dark green). The three Ca2+ ions
found in these CTLD structures altogether are shown as spheres.
(D) DexS tetrasaccharide in complex with SIGN-R1.
(E) Dex disaccharide in complex with SIGN-R1.
(F) Sialic acid in complex with SIGN-R1. Relevant residues are drawn as capped sticks and labeled for SIGN-R1.
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the CTLD superfamily sequences: the ‘‘EPN’’ motif (residues
285–287) that belongs to the LLR and the ‘‘WND’’ motif (residues
302–304) from the b4 strand (Figure S1C). Interestingly, the
Asn303 in SIGN-R1, which is part of the ‘‘WND’’ motif, is not
coordinating the calcium ion (Figure S1A) as occurs in the other
known structures of sugar-binding C-type lectins either alone or
in complex with a ligand (Figure S1B). Structural analysis also re-
veals that the LLR region from SIGN-R1 presents a different
conformation among all reported CTLD members (Figure 2C).
The cavity in which secondary calcium ions (i.e., Ca2 and Ca3)
are located in human DC-SIGN is occupied by the LLR loop in
SIGN-R1, therefore avoiding interaction with these two calcium
atoms (Figure S1D). The L2 loop has been observed in two
different conformations (closed and open) in DC-SIGNR, de-
pending on the presence or absence of the secondary calcium
ions. In SIGN-R1, the L2 loop is folded in the closed conforma-
tion (Figure 2C) without the presence of secondary Ca ions.
Two residues, Ile289 from LLR and Ala263 from L2 (neither
present in DC-SIGN nor in DC-SIGNR), stack with hydrophobic
residues of the cavity masking the secondary calcium-binding
cavity (Figure S1D). The presence of a salt bridge interaction be-
tween Glu291 and Lys306 further stabilizes the conformation of1598 Structure 22, 1595–1606, November 4, 2014 ª2014 Elsevier Ltdthe LLR loop (Figure S1D). It is worth mentioning that crystalliza-
tion with an excess of Ca2+ did not result in any modification of
the 3D structures of SIGN-R1 either in the native or in the
complexes with substrates. Mechanistic implications of these
differences in residues and loop conformations in SIGN-R1
and DC-SIGN/DC-SIGNR cannot be overstated. Mutagenesis
experiments on residues in DC-SIGN (Val351) and in DC-SIGNR
(Ser363), equivalent to Ile289 of SIGN-R1, revealed that they are
the main responsible residues for binding specificity of DC-SIGN
to fucose and DC-SIGN-R to mannose, respectively (Guo et al.,
2004).
Carbohydrate Recognition through Canonical Site
Carbohydrates that bind to SIGN-R1 have been previously
explored with glycan-array tests, suggesting the specificity of
SIGN-R1 for mannose, fucose, and DexS, among other polysac-
charides (Galustian et al., 2004). Besides, SIGN-R1 has been re-
ported to bind sialic acid present on antibodies or glycoproteins
such as C1q complement factor (Anthony et al., 2008; Mizuochi
et al., 1978).
In the SIGN-R1:DexS complex, three of the four monomers
of the asymmetric unit presented electron density for DexS
moieties (one tetrasaccharide unit and two disaccharide unitsAll rights reserved
Figure 3. Primary and Secondary Binding
Sites in SIGN-R1
(A) DexS tetrasaccharide interacting with SIGN-R1
primary binding site. Electrostatic potential on
SIGN-R1 molecular surface is represented with
acidic regions in red and basic regions in blue.
(B) DexS moities (Glc-S) interacting with SIGN-R1
secondary binding site.
(C) Model of polyribitol phosphate (blue sticks)
docked over the SIGN-R1 secondary binding site.
Sulfate molecules (yellow sticks) observed in the
crystal structure of SIGN-R1 are superimposed for
comparison.
(D) Model of CPS14 (blue sticks) docked over
SIGN-R1 secondary binding site. Glc-S molecules
(yellow sticks) as observed in the SIGN-R1:DexS
complex are superimposed for comparison.
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Basis for Selective Recognition by SIGN-R1respectively, see Figure 1B) in the Ca2+-mediated primary
binding site of the lectin (Figures 2D and 2E; Figure S2). The
Ca2+-mediated interactions with dextran depend on the pres-
ence or absence of a sulfate molecule attached to the glucose
sugar. When the sugar contains a sulfate molecule (as occurs
in the tetrasaccharide and one of the disaccharides; Figure 2D),
the sugar ring interacts with calcium through the O1 and estab-
lishes hydrogen bonds between its OH-1 with Asn287 and
Asn288, the OH-2 with Glu285, and the OH-3 with Asn303.
When the sugar does not possess this sulfate moiety, interaction
with Ca2+ is made through the OH-4, whereas OH-3 interacts
with residues Asn287 and Asn288 (Figure 2E). It is worth noting
that due to SIGN-R1’s conformation of LLR, Asn288 plays a
key role in carbohydrate binding but not in binding of one of
the secondary Ca2+ as occurs in human DC-SIGN(R). Protein in-
teractions with the second sugar ring are conserved in all three
DexS complexes (Figures 2D and 2E). The tetrasaccharide
extends its binding through rings three and four by hydrophobic
interactions with Pro251 and Phe312. The fourth ring also estab-
lishes hydrogen bonds with Gln213 (Figure 2D).
In the crystal structure of the SIGN-R1:NeuAc complex, all four
monomers of the asymmetric unit present the sialic acid
attached (Figures 2F and S2). The carboxylic group of the sialic
acid replaces the interaction of the twowater molecules of native
SIGN-R1 in the octahedral coordination of the calcium ion. Sialic
acid is strongly stabilized by SIGN-R1 because most of residues
involved in calcium binding (Glu285, Asn287, Glu292) also
interact with sialic acid, yielding a large hydrogen bond interac-
tion network (Figure 2F). Interestingly, as also observed in SIGN-Structure 22, 1595–1606, November 4, 2014 ªR1:DexS complexes, the Asn288 contrib-
utes to this network interaction in SIGN-
R1.
A Secondary Binding Site in
SIGN-R1
Analysis of the density maps of SIGN-
R1:DexS complex revealed the presence
of three well-defined molecules of D-
glucose-4-sulfate (Glc-S) at the opposite
face of the canonical binding site (Fig-
ure 3B). This secondary site is a 30-A˚long basic groove that is formed by loops connecting a1 and
a2, a3 and b20, and by the lower lobe b sheet. Glc-S molecules
occupy the positions of the sulfate molecules S3–S5 found in
the native structure (Figure 2). Remarkably, both the sulfate moi-
ety and the glycan part of Glc-S are well stabilized in the SIGN-
R1:DexS complex (Figures 3B and S2E).
The repetitive disposition of sulfate/sugar molecules recog-
nized by SIGN-R1 through this secondary binding site pushed
us to explore SIGN-R1 binding to other cellular components
sharing a similar repetitive structure. Teichoic acids (TAs),
one of the main components of the cell wall of all gram-positive
bacteria, are formed by repeating units of sugar-phosphate
chains (Weidenmaier and Peschel, 2008). These glycopolymers
are frequently formed by glycerol or ribitol groups linked by
phosphodiester bridges as in TAs from Staphylococcus aureus
or Listeria monocytogenes (Weidenmaier and Peschel, 2008).
Docking calculations reveal that polyribitol phosphate chain
of TAs nicely fits into SIGN-R1’s secondary binding site with
phosphate moieties superimposing onto the S3–S5 molecules
found in SIGN-R1 (Figure 3C). Another repetitive structure is
that of capsular pneumococcal polysaccharide 14 (CPS14;
Figure 1). It has been found that SIGN-R1 binds preferentially
to this capsular polysaccharide (Kang et al., 2004). Docking
calculations also show binding of CPS14 to this region of
SIGN-R1 (Figure 3D). Docked sugar rings replace the crystal-
lographic glucose molecules found in the SIGN-R1:DexS
complex.
The additional secondary binding site in SIGN-R1 is calcium
independent and structurally not related to the canonical2014 Elsevier Ltd All rights reserved 1599
Figure 4. Binding of Polysaccharides to SIGN-R1 Is Less Sensitive to EDTA Than Human DC-SIGN
(A) CHO cells expressing neomycin (CHO/control), mouse DC-SIGN (CHO/mDC-SIGN), mouse SIGN-R1 (CHO/mSIGN-R1), and human DC-SIGN (CHO/hDC-
SIGN) are stained with(+)/without() specific antibodies as indicated at the right side.
(B) Each CHO cell was incubated with(+)/without() FITC-dextran (500 kDa, 10 mg/ml) for 1 hr followed by fluorescence-activated cell sorting (FACS) analysis.
(C) Each CHO cell was incubated with(+)/without() PE-CPS14 (60 mg/ml) for 5 hr followed by FACS analysis.
(D) Each CHO cell was incubated with(+)/without() FITC-dextran (10 mg/ml) and EDTA (0 to 2.25 mM) for 1 hr followed by FACS analysis.
(E) Percent values for mean fluorescence index (MFI) of each flow cytogram in (D) were plotted, where 100% is for FITC-dextran incubated without EDTA and 0%
for no FITC-dextran.
(F) Each CHO cell was incubated with(+)/without() PE-CPS14 (60 mg/ml) and EDTA (0–2.00 mM) for 5 hr followed by FACS analysis.
(G) Percent values for MFI of each flow cytogram in (F) were plotted, where 100% is for PE-CPS14 incubated without EDTA and 0% for no PE-CPS14. Data in (D)–
(G) represent one of three independent experiments showing similar results, respectively.
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Basis for Selective Recognition by SIGN-R1binding site. Whereas the binding of SIGN-R1 to micro-
bial polysaccharides is calcium dependent (Galustian et al.,
2004; Nagaoka et al., 2005; Takahara et al., 2004); i.e.,
EDTA at 5 mM or higher concentration prevents SIGN-R1
from binding to its polysaccharide ligands. This implies that,
although the primary and secondary binding sites are spatially
separate, polysaccharides might use both sites to bind SIGN-
R1. In agreement with this, it has been reported that SIGN-R1
can only bind to dextrans with high molecular weights but
other SIGNs can bind to dextrans with high as well as lower1600 Structure 22, 1595–1606, November 4, 2014 ª2014 Elsevier Ltdmolecular weights (Takahara et al., 2004). To test this model,
we compared the polysaccharide-binding activities of SIGN-
R1 with those of human DC-SIGN (hDC-SIGN), which lacks
a calcium-independent secondary binding site. In both cases
of FITC-labeled dextran (500 kDa) and PE-labeled CPS14,
the CHO cells expressing SIGN-R1 were able to bind these
polysaccharides at 0.25–0.5 mM higher concentration of
EDTA than the CHO cells expressing hDC-SIGN (Figure 4).
This may indicate that SIGN-R1 contains an extra calcium-in-
dependent binding site for dextran and CPS14, makingAll rights reserved
Figure 5. Model of Interaction between SIGN-R1 and a-2,6 Sialylated
Antibody
Superimposition of the crystal structure of SIGN-R1:NeuAc (blue ribbon) with
the crystal structure of a-2,6 sialylated antibody (molecular surface in brown
for chain A and in green for chain B). Canonical binding site of SIGN-R1 is
represented with the Ca ion (green sphere) and residues coordinating it (blue
capped sticks). The LLR loop is labeled. The secondary binding site of SIGN-
R1 is located at the opposite face where sulfate molecules (represented as
capped sticks) are found. Oligosaccharides attached to Fc are represented as
orange-capped sticks. The terminal a-2,6 sialic acid was not visible in the
crystal structure; the coordinates for this terminal sugar have been taken from
the energy-minimized model. SIGN-R1:Fc interaction mediated by sialic acid
carboxylate would be the starting anchor for further interaction with other
sugars from the carbohydrate moiety linked to Fc. A complementarity exists
between the protein surfaces of the SIGN-R1 receptor and the antibody,
pointing to a protein-protein interaction upon glycan recognition.
Structure
Basis for Selective Recognition by SIGN-R1their binding less sensitive to EDTA treatment, compared to
hDC-SIGN.
Implications in Anti-inflammatory Activity of
Intravenous Ig
SIGN-R1 plays an essential role in the anti-inflammatory process
induced by IVIG (Anthony et al., 2008). In this process, SIGN-R1
specifically recognizes a-2,6 sialylated antibodies instead of
a-2,3 sialylated antibodies. According to our study on the SIGN-
R1:NeuAc complex, SIGN-R1 interacts with sialic acid through
the carboxylate moiety. The atomic resolution of an a-2,3 sialy-
lated antibody (PDB code 1MCO; Guddat et al., 1993) shows
the carboxylic group of sialic acid occluded and facing the inner
part of the antibody, therefore it is not able to interact with
SIGN-R1 as found in the SIGN-R1:NeuAc complex.
To shed more light on the interaction between SIGN-R1 and
silalylated Fc, we solved the high-resolution structure of a human
a-2,6 sialylated antibody Fc portion by X-ray crystallography (Ta-
ble 1; Figure S3A). The density maps of the a-2,6 Fc structure
were of excellent quality and allow us to trace almost the com-
plete glycan chain but without the terminal sialic acid that was
not visible in our maps (Figure S3B), indicating a high flexibility
of this terminal sugar. The crystal structure of an a-2,6 sialylated
antibody has been reported (PDB code 4BYH; Crispin et al.,
2013). Despite completely different crystallization conditions,
our a-2,6 Fc structure was nearly identical to the reportedStructure 22, 1595–16a-2,6 sialylated antibody in both the backbone (rmsd of
0.563 A˚ over 294 aligned Ca atoms) and the sugar conformation
(Figures S3C and S3D). Interestingly, the a-2,6 Fc structure
shows the carboxylic group of arm 6 terminal sialic acid as
completely exposed (Figures S3D and S3E), allowing the interac-
tion with SIGN-R1 as observed in the SIGN-R1:NeuAc complex.
Molecular dynamic (MD) simulations further indicate that a-2,3
and a-2,6 sialylations result in two different conformers for the
sialic acid. In a-2,3 sialylated antibody both galactose and sialic
acid rings establish strong interactions with the protein (Figures
S4 and S5; Movie S1), provoking the carboxylate moiety being
occluded (accessible surface of 0.3 A˚2). In the a-2,6 sialylated
antibody, the galactose interacts with the protein while the
sialic acid is completely exposed (accessible surface of 5 A˚2),
releasing some regions of Fc antibody (Figures S5 and S6;Movie
S2). This high flexibility is in agreement with what we observe in
our crystal structures.
Summing up, whereas the a-2,6 link provokes exposition of
carboxylic acid of the sialic acid, the a-2,3 variant does not.
Therefore only the a-2,6 link could allow Fc recognition by
SIGN-R1. Superimposition of both SIGN-R1 and Fc structural
models (Figure 5) indicates that their interaction mediated by
sialic acid carboxylate would be the starting anchor for further
interaction with other sugars from the carbohydrate moiety
linked to Fc (as observed in the DexS tetrasaccharide in complex
with SIGN-R1) and to allow interaction between both protein
surfaces (specially through the LLR loop from SIGN-R1 and
with the exposed Fc region in the a-2,6 variant predicted with
MD). It has been proposed that structural changes in Fc upon
sialylation would be responsible for the interaction with the re-
ceptor (Sondermann et al., 2013a) and that the high-salt crystal
structure of the a-2,6 sialylated antibody reported previously
(Crispin et al., 2013) would not be representative of the confor-
mational changes found in solution (Sondermann et al.,
2013b). Considering that we have obtained a nearly identical
structure for a-2,6 sialylated antibody in the absence of salt, it
is expected that changes in the Fc should be more related
with those predicted by ourMD simulations. These results would
provide an structural explanation for the observed specificity of
SIGN-R1 to a-2,6 sialylated antibodies in the inhibition of the
inflammatory response (Anthony and Ravetch, 2010).
Complement Fixation Pathway for Pathogens Initiated
by SIGN-R1
SIGN-R1 presents a single calcium-binding site that corre-
sponds to the primary carbohydrate-binding site observed in
other CTLDs. The specific conformation of SIGN-R1 for the
LLR loop avoids stabilization of Ca2 and Ca3.
Crystal structures of SIGN-R1 alone and in complex with DexS
reveal the presence of sulfate or Glc-S moieties, respectively,
both of which are attached to SIGN-R1’s calcium-independent
secondary binding site in a repetitive manner. This additional
binding site is located at the opposite face of the canonical
calcium-dependent binding site without apparent structural
connection among them. Docking calculations indicate that pol-
yribitol phosphate (backbone of teichoic acids of somemicrobial
pathogens), which follows the same repetitive pattern, can be
accommodated in this secondary binding site. The same result
is also observed for docking with a model of the capsular06, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1601
Figure 6. Proposed Mechanism of Path-
ogen Recognition and Complement Activa-
tion Mediated by SIGN-R1
Molecular surface of SIGN-R1 crystal structure is
shown in blue with Ca2+ atoms drawn as yellow
spheres. A model for the extracellular SIGN-R1
tetramer attached to the macrophage membrane
is presented. The carbohydrate recognition
domain of SIGN-R1 can recognize pathogen
components such as CSP through its secondary
binding site that binds the globular portion of C1q
(PDB code 1PK6; Gaboriaud et al., 2003) through
the calcium-dependent binding site.
Structure
Basis for Selective Recognition by SIGN-R1polysaccharides from pneumococcus serotype 14 (CSP14).
Altogether, these results indicate that SIGN-R1 possesses two
separate binding sites. The additional noncanonical binding
site in SIGN-R1 might recognize distinct carbohydrate patterns
from microbial pathogens, such as dextran, teichoic acids, and
CPS14.
SIGN-R1 mediates activation of the classical complement
pathway through direct interaction with C1q and CPS in spleen
(Kang et al., 2006). How exactly these molecules interact to acti-
vate the complement pathway is unknown. C1q is a glycoprotein
and the structure of its recognition domain (Gaboriaud et al.,
2003) and sugar chains has been reported (Mizuochi et al.,
1978). Structures of oligosaccharides attached to C1q are repre-
sented in Figure 1A (or small variants with only one NeuAc at
the end or without the Fuc at the beginning of the chain). In all
cases, the sialic acid is exclusively linked at the C-6 position of
the galactose residue. Furthermore, it has been reported that
SIGN-R1 specifically recognizes IgG molecules that contain
terminal a-2,6 sialic acid linkages (Anthony et al., 2008). The
crystal structure of the SIGN-R1:NeuAc complex reveals that
sialic acid is strongly stabilized by SIGN-R1 at the primary ca-
nonical carbohydrate binding site (but not in the secondary
site) through carboxylic acid in NeuAc. Considering all these
facts, we propose a model that the SIGN-R1 lectin captures
C1q, which is bound to C1r and C1s in serum, via a direct inter-
action between the primary carbohydrate binding site in SIGN-
R1 and the polysaccharides ended by an a-2,6 sialic acid in
C1q, whereas SIGN-R1 also binds to pathogen patterns through
its secondary binding site (Figure 6).
However, seeing that the binding of microbial polysaccha-
rides to SIGN-R1 expressed on cell lines is less but still sensitive
to EDTA treatment (Figure 4), this model for simultaneous
recognition of two different polysaccharides by SIGN-R1 (Fig-1602 Structure 22, 1595–1606, November 4, 2014 ª2014 Elsevier Ltd All rights reservedure 6) may not explain all the binding
events mediated by SIGN-R1 on splenic
marginal zone macrophages. SIGN-R1
protein in spleen and lymph nodes and
expressed in cell lines exists in highly
complex forms that have much higher
molecular weights than tetrameric forms
(Kang et al., 2003). In addition, cell lines
expressing SIGN-R1 cannot bind %
40 kDa dextrans, whereas other CLRs
such as SIGN-R3 and Langerin can
bind 40 kDa of dextran (Takahara et al.,2004). Based on these observations, we propose that on the
surface of splenic marginal zone macrophages, where SIGN-
R1 is expressed as large complexes of multiple tetramers, mi-
crobial polysaccharides such as dextran and CPS14 bind to
SIGN-R1 on both of its calcium-dependent and -independent
sites. Meanwhile, Ca-dependent primary binding sites in a sig-
nificant number of SIGN-R1 molecules in the same complexes
might bind to the terminal a-2,6 sialic acid of polysaccharides
in C1q (Figure 6). Therefore, the interaction with two different
polysaccharides would allow SIGN-R1 complexes to efficiently
identify and bring the microbial pathogen to the proximity of
C1q, thus promoting the assembly of a C4bC2a, i.e., C3 conver-
tase, and the C3 fixation of microbial polysaccharides. This
mechanism could allow the efficient activation and fixation of
C3 by S. pneumoniae and CPS upon entry into the bloodstream
and spleen. Then, within minutes of intravenous injection, both
CPS and S. pneumoniae are fixed with C3 to be sequestered
from marginal zones to follicles, and much of the C3 in serum
is catabolized (Kang et al., 2006).
Recent evidence suggests that complement and cellular com-
plement receptors also play important roles in the localization
and retention of nonbacterial pathogens to follicular dendritic
cells, especially HIV-1 (Feinberg et al., 2007). Interestingly
SIGN-R1 binds viral glycoproteins as do human DC-SIGN(R)
(Curtis et al., 1992). DC-SIGN binding to HIV can promote viral
infection of T cells (Chehimi et al., 2003). It is worth noting that
oligosaccharides present on the envelope of various viruses
such as HIV also contain terminal a-2,6 sialic acid linkages (Var-
chetta et al., 2013). Therefore, in the mechanism we proposed,
viral glycoproteins could block the interaction of sialylated C1q
or Ig with SIGN-R1 through its primary binding site, thus avoiding
efficient recognition and response against the pathogen by the
immune system.
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Production of SIGN-R1
A DNA construct encoding the soluble CRD protein of SIGN-R1 (CRD_SIGN-
R1) was generated by amplifying the CRD domain from SIGN-R1 cDNA by
PCR, cloned into a mammalian expression vector containing signal sequence
and FLAG epitope and sequenced, as described previously (Park et al., 2008).
Themammalian expression vector encoding this FLAG-tagged CRD_SIGN-R1
(GenBank accession number EU697459) was transfected into Chinese
hamster ovary (CHO) cells (CHO-S cells, GIBCO, Life Technologies) using
Lipofectamine 2000 reagent (Life Technologies) following the manufacturer’s
instructions. Stable CHO cell lines producing the soluble or mature form of
FLAG-tagged CRD_SIGN-R1 protein that consists of an N-terminal, 9 amino
acid long FLAG epitope and a 134 amino acid long CRD domain of SIGN-R1
(residues from Cys192 to Gly325) were generated following selection with
G418 (1.5 mg/ml) as described previously (Kang et al., 2004). CRD_SIGN-R1
protein was purified from the supernatant of stably transfected CHO cell cul-
ture with an affinity column using anti-FLAG M1 agarose gel (Sigma-Aldrich)
following the manufacturer’s instructions.
Binding Experiments
The cDNA encoding an open reading frame of human DC-SIGN (hDC-SIGN)
was cloned by PCR from a human thymic cDNA library (Clontech). CHO cells
expressing hDC-SIGN were generated and cloned under G418 (1.5 mg/ml)
selection pressure as described above. Stable FITC-labeled dextran (FITC-
dextran, 500 kDa) was purchased from Sigma-Aldrich. PE-labeled CPS14
(PE-CPS14) was generated at home as follows. Purified CPS14 (lyophilized
pneumococcal polysaccharide powder type 14) was purchased from ATCC,
and 2 mg of CPS14 was biotinylated in essence as described previously (Col-
ino and Snapper, 2007; Koesling et al., 2001). After extensive dialysis against
Dulbecco’s PBS (GIBCO, Life Technologies), 500 mg of biotinylated CPS14 in
DPBS was mixed with 25 mg of PE-conjugated streptavidin (BD Biosciences)
by rotator at 4C overnight. CHO cells expressing SIGN-R1 (Kang et al.,
2004) and hDC-SIGN (see above) were trypsinized and plated into 12-well
plates. When the plated CHO cells became confluent, each well was replen-
ished with fresh media containing FITC-dextran (10 mg/ml in final concentra-
tion) or PE-CPS14 (60 mg/ml in final concentration) with/without graded doses
of EDTA. Then the plates were further incubated at 5% CO2, 37
C for 1 hr
(FITC-dextran) or 5 hr (PE-CPS14) before being analyzed for polysaccharide
uptake with a LSR II flow cytometer (BD Biosciences).
Production of a-2,6 Sialylated Antibody
Hypersialylated human Fcs were generated as previously described, with mi-
nor modifications (Anthony et al., 2008). Briefly, IVIG-derived Fc fragments
were treated with 2,3/6 sialidase to remove sialic acid residues. Fc fragments
(30 mg/ml) were incubated in 50 mMMOPS, pH 7.2, 20 mMMnCl2 with 10 mM
uridine diphosphate-galactose and 25 mU/10mg substrate of b1-4 galacto-
syltransferase for 48 hr at 37C. Next, the Fcs were sialylated in 50 mM
MOPS, 20 mM MnCl2, pH 7.2, and 10 mM MnCl2, supplemented with
10 mM CMP-sialic acid, 100 mU/ml a2-6 sialyltransferase at 37C for 48 hr.
The glycosylation reactions were confirmed by lectin blotting with Erythrina
Cristagalli Lectin (terminal galactose), and Sambucus Nigra Lectin (terminal
2,6 sialic acid).
Crystallization of SIGN-R1 and SIGN-R1 Complexes
Crystallization trials were performed at 18C as previously described (Silva-
Martin et al., 2009). Good quality crystals grown by mixing 1 ml of
CRD_SIGN-R1 (4 mg/ml in 20 mM Tris/HCl pH 7.5 and 100 mM NaCl)
with 1 ml of precipitant solution from commercial JCSG+ crystallization grid
consisting of 0.1 M Bis-tris pH 5.5 and 1.6 M (NH4)2SO4 (Quiagen). Drops
were equilibrated against 500 ml. The best SIGN-R1 native crystal appears
after 2 weeks with a maximum dimension of approximately 0.30 3 0.28 3
0.10 mm. Complexes of SIGN-R1 with dextran sulfate polysaccharide were
obtained by incubation of a 4 mg/ml protein solution with 5 mM CaCl2 and
3% dextran sulfate (Hampton research additive number 51). Best complex
crystals appear after 3 weeks with maximum dimensions of approximately
0.20 3 0.18 3 0.10 mm. Complexes of the SIGN-R1 with sialic acid were
obtained after overnight soaking of SIGN-R1 native crystals with precipitantStructure 22, 1595–16solution supplemented with 10 mM sialic acid (SIGMA). All crystals were
cryoprotected into a mixture of 3M Li2SO4 with crystallization conditions in a
1:1 volume proportion. Then, crystals were flash-cooled in liquid nitrogen
and maintained at 100 K during data collection.
Crystallization of the Glycosylated Human Fc
Crystals were obtained by mixing 1 ml of Fc-Sial (9 mg/ml) with 3 ml of precip-
itant solution consisting of 0.1 M HEPES pH 7.0 and 0.1 M PEG 6000 under
hanging drop vapor diffusion experiment at 18C. The best Fc-Sial crystals
appear after 2 weeks, reaching maximum dimensions of approximately
0.70 3 0.30 3 0.40 mm. Before data collection crystals were cryoprotected
in a solution containing mother liquor and 25% glycerol. Then, crystals
were flash-cooled in liquid nitrogen and maintained at 100 K during data
collection.
X-Ray Data Collection and Structural Determination
X-ray data sets of CRD_SIGN-R1 native and ligand complexes were collected
using a synchrotron radiation source at the ESRF (Grenoble). The native crys-
tals data set was measured with an ADSC Quantum Q315r detector at beam-
line ID23-1. SIGN-R1:DexS data sets were measured with an ADSC Quantum
4 detector at beamline ID14-2. SIGN-R1:NeuAc data sets were measured with
a MAR225 detector at beamline ID23-2. All data sets were processed using
MOSFLM (Moras et al., 1992) and scaled using SCALA from the CCP4 pack-
age (CCP4, 1994). All SIGN-R1 crystals belong to monoclinic C2 space group
containing four independent molecules in the asymmetric unit. Data process-
ing results are summarized in Table 1.
The native structure was determined by molecular replacement with
MOLREP program from the CCP4 package (CCP4, 1994) using human DC-
SIGN structure (PDB code ISL4) with 69% of identity, as initial model. Molec-
ular replacement rotation and translation correlation coefficients were ranked
and yielded four solutions well above the background; the final solution for R
and Scor were 39.7% and 57.3%, respectively.
X-ray data sets for sialylated Fcweremeasuredwith aQ315r ADSCCCDde-
tector on ID14-4 beamline (ESRF, Grenoble). Crystals belong to the P212121
orthorhombic space group containing two molecules in the asymmetric
unit. Structural determination was done by molecular replacement using a
monomer of the human IgG1 structure (PDB code IHZH), which shows 99%
sequence identity for the Fc portion. Molecular replacement was performed
with the MOLREP using a 3.5 A˚ cutoff limit for resolution. Four single and un-
ambiguous solutions were obtained, with final correlation coefficients of 25%
for R and 54% for Scor.
In all cases, initial refinement and map calculations were carried out using
CNS (Bru¨nger et al., 1998). Bulk solvent correction was applied during the
refinement. Water molecules were gradually added to peaks higher than 3s
in Fo-Fc mapswithWATERPICK program routine ofCNS program. Iterative cy-
cles of refinement and manual model building were done. Model building was
performed with Coot (Emsley and Cowtan, 2004) program. Further refinement
using maximum likelihood methods was performed with the REFMAC5 from
the CCP4 package (CCP4, 1994) and PHENIX (Adams et al., 2010) program.
The final geometry of the structures was evaluated using the program
PROCHECK (Laskowski et al., 1993). All the final models presented good ste-
reochemistry parameters and R and Rfree values (Table 1).
Docking Calculations
Two polysaccharides were docked at the SIGN-R1 secondary binding site:
the capsular pneumococcal polysaccharide 14 (CPS14) and the polyribitol
phosphate. The protein-ligand docking experiments were performed to test
whether it was possible to find a compatible model with the experimental
evidence of the repetitive Glucose-S/sulfate moieties observed in the
crystallographic studies. To this end, we first docked the CPS14, one of the
highest affinity capsular polysaccharide reported to bind to SIGN-R1 (Kang
et al., 2004). The 3D structure of CPS14 was modeled in the sweet server
(http://www.glycosciences.de/modeling/sweet2/doc/index.php), using the
unit repetitive tetrasaccharide of the S. pneumoniae serotype 14 bGal(1,4)-
bNAG(1,3)-bGal(1,4) bGlc(1,6)- bNAG as a template. Molecular docking was
carried out using GOLD (Genetic Optimization for Ligand Docking) software
(Verdonk et al., 2003), using the genetic algorithm (GA). This method allows
a partial flexibility of protein and full flexibility of the ligand. For each of the06, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1603
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Basis for Selective Recognition by SIGN-R125 independent GA runs, a maximum number of 100,000 operations were per-
formed on a set of five groups with a population size of 100 individuals. Default
cut-off values of 2.5 A˚ (dH-X) for hydrogen bonds and 4.0 A˚ for Van Deer Waals
distance were used. When the top three solutions attained rmsd values within
1.5 A˚, GA docking was terminated. The rmsd values for the docking calcula-
tions are based on the rmsd matrix of the ranked solutions. We observed
that the best-ranked solutions were always among the first ten GA runs, and
the conformation of molecules based on the best fitness score was further
analyzed. The Hex6 docking program (Ritchie et al., 2008) was also used to
explore possible modes of interaction of SIGN-R1 with CPS14 models. This
procedure performs a global rotational and translational space scan using
Fourier transformations that rank the output according to surface complemen-
tarity and predicted electrostatic potentials. A list with the best complexes
CPS14-SIGN-R1 was analyzed in a base of available biochemical data to filter
out possible solutions. A similar disposition to that provided by GOLD was
found for the polysaccharide using Hex6.
The 3D structure of (4)-ribitol phosphate was modeled using the Dundee
PRODRG2 server (Schu¨ttelkopf and van Aalten, 2004). Stereochemistry of
the ligand was checked with the Mercury program (Macrae et al., 2008).
Molecular docking was carried out using GOLD (Genetic Optimization for
Ligand Docking) software (Verdonk et al., 2003) in a similar way to that used
for CPS14. The cavity was defined from and to 5 A˚ around the 4 sulfates
(S2–S5), giving freedom of movement to Lys197, Asn204, and Arg246 in
side chain rotamers. The best-ranked solutions were always among the first
10GA runs, and the conformation ofmolecules based on the best fitness score
was further analyzed.
Molecular Dynamics Simulations
Simulations were based on the crystal structure of the human Fc fragment
immunoglobulin reported in this paper. Long simulations were performed to
investigate the dynamics of the sialic acid in positions 2–6 and 2–3. We used
the crystallographic structure of 1MCO (Guddat et al., 1993) as a reference
for the 2–3 conformation. The final glycosides molecules where prepared for
the Glycam_06 (Kirschner et al., 2008) force field, whereas the AMBER
ff99SB (Hornak et al., 2006) force field was used for the protein structure. Pre-
pared structures were immersed in triclinic boxes of TIP3P water molecules
(Jorgensen et al., 1993). Counter ions were also added to maintain electroneu-
trality. Before and after the addition of ions, two minimizations of 10,000 iter-
ations were performed using a steepest descend and conjugated gradient
method.
All minimizations and MD simulations were performed using the GROMACS
4 (Hess et al., 2008). Time steps of 2 fs were used for the integrations of New-
ton’s equations of motion. The simulations have been carried out using peri-
odic boundary conditions with the NPT (N, total number of atoms; P, pressure;
T, temperature) ensemble. Electrostatic interactions were evaluated using the
particle-mesh Ewald (PME) method (Darden et al., 1993) with Van der Waals
interactions truncated at 14 A˚. The systems were then heated and equilibrated
in two steps: (1) 300 ps of MD with restricted position of all atoms of the glyco-
protein and heating whole system from 50 K to 298 K, and (2) 150 ps ofMDwith
restricted position of the backbone atoms. The equilibrated structures were
the starting points for 200 ns MD simulations at constant temperature (298
K) and pressure (1 atm). Bond lengths were constrained using the LINCS
algorithm, and water geometries constrained by SETTLE. Analyses were per-
formed using the GROMACS 4 suite of programs. Demonstration of system
geometries and interactions were done using CHIMERA.
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